FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer

Stable Identifier
R-HSA-2077421
Type
Reaction [binding]
Species
Homo sapiens
Compartment
extracellular region
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
FP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011).
Literature References
PubMed ID Title Journal Year
21711248 Fibroblast growth factors and their receptors in cancer

Haglund, K, Wesche, J, Haugsten, EM

Biochem J 2011
Participants
Input
Output
Participates
as an event of
Disease
Name Identifier Synonyms
female reproductive endometrioid cancer DOID:3001 endometrioid tumor (morphologic abnormality), endometrioid neoplasm
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2012-02-10)
Reviewed
Ezzat, S  (2012-05-15)
Created
Rothfels, K  (2012-01-28)
Cite Us!